These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 26415106)
1. Primary immunodeficiencies and the control of Epstein-Barr virus infection. Palendira U; Rickinson AB Ann N Y Acad Sci; 2015 Nov; 1356():22-44. PubMed ID: 26415106 [TBL] [Abstract][Full Text] [Related]
2. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases. Latour S; Fischer A Immunol Rev; 2019 Sep; 291(1):174-189. PubMed ID: 31402499 [TBL] [Abstract][Full Text] [Related]
3. X-linked lymphoproliferative syndrome. Natural history of the immunodeficiency. Sullivan JL; Byron KS; Brewster FE; Baker SM; Ochs HD J Clin Invest; 1983 Jun; 71(6):1765-78. PubMed ID: 6306053 [TBL] [Abstract][Full Text] [Related]
4. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Hislop AD; Taylor GS; Sauce D; Rickinson AB Annu Rev Immunol; 2007; 25():587-617. PubMed ID: 17378764 [TBL] [Abstract][Full Text] [Related]
5. X-linked lymphoproliferative syndromes and related autosomal recessive disorders. Veillette A; Pérez-Quintero LA; Latour S Curr Opin Allergy Clin Immunol; 2013 Dec; 13(6):614-22. PubMed ID: 24113228 [TBL] [Abstract][Full Text] [Related]
6. Cell-mediated immune responses in man to Epstein-Barr (EB) virus infection. Lai PK; Alpers MP Comp Immunol Microbiol Infect Dis; 1979; 2(4):565-85. PubMed ID: 232867 [No Abstract] [Full Text] [Related]
10. The relationship between Epstein-Barr virus and lymphoma. Bird AG; Britton S Semin Hematol; 1982 Oct; 19(4):285-300. PubMed ID: 6297094 [No Abstract] [Full Text] [Related]
11. Role of human natural killer cells during Epstein-Barr virus infection. Münz C Crit Rev Immunol; 2014; 34(6):501-7. PubMed ID: 25597312 [TBL] [Abstract][Full Text] [Related]
12. Induction and progression of human lymphoproliferative lesions by Epstein-Barr virus. Chappuis BB; Müller-Hermelink HK Environ Health Perspect; 1990 Aug; 88():237-41. PubMed ID: 2176977 [TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus and human disease: immune responses determine the clinical and pathologic expression. Purtilo DT; Sakamoto K Hum Pathol; 1981 Aug; 12(8):677-9. PubMed ID: 6269987 [No Abstract] [Full Text] [Related]
15. Immunodeficiency as a factor in lymphomagenesis. Purtilo DT; Sakamoto K Perspect Pediatr Pathol; 1984; 8(2):181-91. PubMed ID: 6330665 [TBL] [Abstract][Full Text] [Related]
16. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity. Edwards ESJ; Bier J; Cole TS; Wong M; Hsu P; Berglund LJ; Boztug K; Lau A; Gostick E; Price DA; O'Sullivan M; Meyts I; Choo S; Gray P; Holland SM; Deenick EK; Uzel G; Tangye SG J Allergy Clin Immunol; 2019 Jan; 143(1):276-291.e6. PubMed ID: 29800648 [TBL] [Abstract][Full Text] [Related]
17. LYDMA-antigens and immunity against EBV-infected cells Epstein-Barr virus as a model for the study of host-infection interaction. Villa ML; Bombardieri E Int J Biol Markers; 1987; 2(2):125-32. PubMed ID: 2837523 [TBL] [Abstract][Full Text] [Related]